Compare CELH & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CELH | STVN |
|---|---|---|
| Founded | 2004 | 1949 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Containers/Packaging |
| Sector | Consumer Staples | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 5.7B |
| IPO Year | 2008 | 2021 |
| Metric | CELH | STVN |
|---|---|---|
| Price | $27.84 | $19.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 24 | 14 |
| Target Price | ★ $42.19 | $24.47 |
| AVG Volume (30 Days) | ★ 5.8M | 316.8K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 0.33% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $1,318,014,000.00 | N/A |
| Revenue This Year | $26.05 | $7.05 |
| Revenue Next Year | $8.51 | $9.23 |
| P/E Ratio | $58.30 | ★ $27.15 |
| Revenue Growth | ★ 101.65 | N/A |
| 52 Week Low | $23.56 | $12.89 |
| 52 Week High | $66.74 | $27.99 |
| Indicator | CELH | STVN |
|---|---|---|
| Relative Strength Index (RSI) | 45.27 | 34.99 |
| Support Level | $27.23 | $18.87 |
| Resistance Level | $30.19 | $20.63 |
| Average True Range (ATR) | 0.98 | 0.78 |
| MACD | 0.01 | -0.26 |
| Stochastic Oscillator | 32.58 | 14.04 |
Celsius Holdings operates in the energy drink subsegment of the global nonalcoholic beverage market, with 95% of revenue concentrated in North America. It owns three energy drink brands: Celsius, Alani Nu, and Rockstar Energy. It focuses on product innovation and marketing while outsourcing manufacturing and packaging to third-party co-packers and distribution to PepsiCo. The firm issued convertible preferred shares following PepsiCo's investments in 2022 and 2025, giving the latter an 11% stake in Celsius.
Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries. The company operates through two segments: a Biopharmaceutical and Diagnostic Solutions segment, which offers an integrated, end-to-end portfolio of products, processes, and services spanning the full drug lifecycle; and an Engineering segment, which designs, develops, and manufactures advanced machinery for pharmaceutical manufacturing, covering visual inspection, assembly and packaging, glass converting, and serialization. Stevanato's revenue is geographically diversified, with approximately 60% of sales generated in Europe, the Middle East, and Africa, 30% in North America, 8% in Asia-Pacific, and 2% in South America.